Name

Renjing Biology

Legal name

RinuaGene Biotechnology Co., Ltd.

Website

https://rinuagene.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

mRNA Therapeutics and Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• MRNA therapeutics
• Therapeutic vaccines
• Lipid nanoparticle delivery
• Protein replacement therapy
• Prophylactic vaccines

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Distribution channels1 record

Marketing channels4 records

Core offering

Renjing Biology (RinuaGene) is a clinical-stage biopharmaceutical company developing mRNA-based therapeutics and vaccines. Its pipeline includes therapeutic mRNA-LNP vaccines for HPV-related diseases (RG002 for cervical precancerous lesions and cancer), prophylactic mRNA vaccines (RG004 for RSV, RG003 for seasonal and pandemic influenza), and in vivo protein replacement therapies for rare diseases and anti-aging applications. The company operates four core technology platforms: targeted delivery (LNP), RNA engineering (linear mRNA and circular RNA), CMC manufacturing, and data science/AI for sequence and antigen design.

Product overview

Renjing Biology (RinuaGene) is developing a diversified portfolio of mRNA-based therapeutics and vaccines across three main categories: therapeutic vaccines (primarily HPV-related products including RG002 for cervical pre-cancer and malignancies), in vivo protein replacement therapies (for rare diseases and anti-aging), and prophylactic vaccines (seasonal flu, pandemic flu, and RSV). The company operates four core technology platforms—linear mRNA, circular RNA, LNP targeted delivery, and CMC—to support its product pipeline from discovery through clinical production.

Differentiator

Problem solved

Functional benefit

Products and services

• RG002 (RG002 Injection) Proprietary HPV therapeutic mRNA-LNP vaccine targeting HPV16/18-related cervical intraepithelial neoplasia grade 2/3 (CIN2/3), cervical cancer, and other HPV-related malignancies. Uses multi-antigen design covering E6, E7, and E2 proteins from HPV types 16 and 18. For patients with HPV-related precancerous lesions and malignancies.
• RG002-02 HPV-related therapeutic vaccine pipeline product under development.
• RG002-03 Therapeutic mRNA vaccine for recurrent respiratory papillomatosis (RRP) and condyloma acuminatum.
• RG002-04 HPV-related therapeutic vaccine pipeline product under development.
• RG-lead-011 mRNA-based in vivo protein replacement therapy for rare diseases.
• RG-lead-012 mRNA-based in vivo protein replacement therapy for anti-aging applications.
• RG-lead-013 Undisclosed mRNA-based in vivo protein replacement therapy product.
• RG-lead-014

Quantifiable outcome

• Phase I/IIa trial: 100% effectiveness demonstrated at the lowest dose with excellent safety at all dose levels
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical CollegecoreStrategic or Co-development Partner · 16 October 2024Joint research collaboration for mRNA delivery system development. The institute is joint corresponding author on Advanced Science publication regarding novel ionizable lipid (4S)-KEL12. Collaborative partner in developing mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies published in Molecular Therapy.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Moderna: Moderna is the global mRNA therapeutics leader with multiple mRNA-LNP vaccine and therapeutic programs including HPV-related candidates. It has substantially greater capital, manufacturing scale, and clinical pipeline breadth, making it the most relevant broad incumbent for Renjing's mRNA-LNP therapeutic vaccine strategy.
• BioNTech: BioNTech is a leading mRNA therapeutics company with oncology vaccine programs (including HPV-related FixVac platform) and infectious disease vaccines. Its focus on individualized and off-the-shelf mRNA cancer immunotherapies directly parallels Renjing's RG002 multi-antigen design approach.
• CSPC Pharmaceutical Group: CSPC is a major Chinese pharmaceutical company that has developed its own mRNA vaccine (SYS6006) for COVID-19. As a large, established Chinese pharma with mRNA capabilities, it is a broad incumbent peer with substantially greater commercial infrastructure.
• Translate Bio (Sanofi): Translate Bio, now a Sanofi subsidiary, developed an mRNA platform with LNP delivery for vaccines and protein replacement. Its acquisition by a major pharma validates the strategic value of mRNA-LNP platforms and represents the most likely M&A pathway for Renjing.

Direct peers

• CureVac: CureVac is a clinical-stage mRNA therapeutics company developing prophylactic vaccines, oncology vaccines, and protein replacement therapies. Its similar pipeline breadth (cancer, infectious disease, protein replacement) and clinical-stage status make it a directly comparable mRNA pure-play peer.
• Stemirna Therapeutics: Stemirna is a Chinese mRNA vaccine and therapeutics developer with COVID-19 and cancer vaccine programs. As a China-based mRNA clinical-stage peer operating from Shanghai, it represents the most direct head-to-head competitive comparison for Renjing in the domestic market.
• Abogen Biosciences: Abogen Biosciences is a Chinese clinical-stage mRNA company developing COVID-19 and other mRNA-LNP vaccines including oncology applications. It is a direct peer in the Chinese mRNA-LNP therapeutic vaccine space, competing for similar talent, partnerships, and clinical development resources.
• Arcturus Therapeutics: Arcturus is a clinical-stage mRNA medicines company developing vaccines and therapeutics, including a self-amplifying mRNA platform and LNP delivery technology. Its direct focus on mRNA-LNP delivery optimization and oncology applications makes it a closely comparable peer in technology and stage.

Emerging players

• Walvax Biotechnology: Walvax is a Chinese vaccine developer that has advanced mRNA COVID-19 vaccine candidates. As a domestic Chinese vaccine peer with mRNA capabilities and HPV vaccine expertise (Cecolin), it represents a regional emerging player with both traditional and mRNA platform capabilities.

Regional players

• Immorna Biotherapeutics: Immorna is a clinical-stage Chinese mRNA company developing both conventional and self-amplifying mRNA vaccines for infectious disease and oncology. As a regional Chinese mRNA peer, it competes with Renjing for similar clinical, regulatory, and commercial pathways in the China market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Renjing Biology